stockrow
Friday 6 November 2026
Export MANE’s income statement to Excel — free account
Veradermics Incorporated
MANE Healthcare Biotechnology
138.19
9.59
+7.46%
Follow MANE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 9 | 9 | 122 | +275.1% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (26) | (70) | (79) | +164.3% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (26) | (70) | (136) | +164.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (35.94) | (111.91) | (45.88) | +211.4% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (32.14) | (96.11) | (3.04) | +199.0% | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (32.14) | (96.14) | (3.04) | +199.1% | ||||||
| Book value | — | — | — | — | — | — | — | — | (65.78) | (162.43) | 20.12 | +146.9% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 1 | 16 | +1.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (24) | (72) | (123) | +202.3% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (24) | (72) | (123) | +202.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 51 | 143 | 813 | +182.1% | |||||
| Net debt | — | — | — | — | — | — | — | — | (53) | (142) | (820) | +167.2% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (48) | (121) | 814 | +149.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (80.11) | (20.86) | (80.1) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 98.38 | 0.00 | +98.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 19 | 21 | — | +10.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Business profile
Veradermics Incorporated vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMVT Immunovant, Inc. | $5.9B | — (loss-making) | — | — | n/m | −5.96% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BLTE Belite Bio, Inc. Sponsored ADR | $5.8B | — (loss-making) | — | — | n/m | +64.67% (above 0%: growing) | — | 0.00% | Compare |
| CGON CG Oncology, Inc. | $5.7B | — (loss-making) | — (loss-making) | +2,125.00% (above 0%: growing) | n/m | −67.60% (below 0%: shrinking) | (239.24%) | (7,467.68%) | Compare |
| KOD Kodiak Sciences Inc. | $5.7B | — (loss-making) | — | — | n/m | −33.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SRRK Scholar Rock Holding Corporation | $5.5B | — (loss-making) | — (loss-making) | +605.03% (above 0%: growing) | n/m | +8.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PTCT PTC Therapeutics, Inc. | $5.5B | — (loss-making) | 42.2× | +69.57% (above 0%: growing) | n/m | +90.28% (above 0%: growing) | 93.39% | 7.02% | Compare |
| MANE Veradermics Incorporated | $5.4B | — (loss-making) | — | — | n/m | −8.81% (below 0%: shrinking) | — | 0.00% | |
| COGT Cogent Biosciences, Inc. | $5.1B | — (loss-making) | — (loss-making) | −69.41% (below 0%: shrinking) | n/m | −42.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ERAS Erasca, Inc. | $4.6B | — (loss-making) | — | — | n/m | −4.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $5.6B | — | — | +337.30% | — | −5.31% | 0.00% | 0.00% |
Largest institutional holders 13F, quarter to 30 June 2026
Held by institutions
81.58%
Held by the ten largest
49.81%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 4.17m | 9.98% | 0.00 |
| Fidelity (FMR) | 3.20m | 7.67% | +1.41m |
| SR One Capital Management, LP | 2.40m | 5.75% | 0.00 |
| Deep Track Capital, LP | 2.00m | 4.79% | +1.50m |
| Citadel Advisors | 1.88m | 4.49% | +52.10k |
| Siren, L.L.C. | 1.66m | 3.96% | +150.00k |
| BlackRock | 1.59m | 3.81% | +1.31m |
| VIKING GLOBAL INVESTORS LP | 1.56m | 3.74% | −129.06k |
| Vanguard | 1.18m | 2.83% | +372.96k |
| JPMorgan Chase | 1.17m | 2.79% | +189.42k |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
Veradermics Incorporated (MANE) Latest News
No news at this impact. Lower the threshold for more.
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company developing treatments for aesthetic and dermatological conditions. Its initial focus is pattern hair loss, a progressive condition that affects both men and women. The company has no products approved for commercial sale.
Its lead candidate, VDPHL01, is an oral, non-hormonal treatment being studied for pattern hair loss. It contains minoxidil in an extended-release formulation, designed to release the drug over time. Minoxidil is already available as a topical hair-loss treatment, and an immediate-release oral version is used off label for hair loss. Veradermics designed VDPHL01 to deliver minoxidil for hair growth while minimizing the risk of cardiac activity.